[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.129.152. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
January 22/29, 2003

Financial Consequences of Drug Benefit Plans

Author Affiliations
 

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

JAMA. 2003;289(4):423-424. doi:10.1001/jama.289.4.423-a

In Reply: Drs Clark and Garis describe what is commonly referred to as the "spread" on prescription drugs. Employers sometimes negotiate a rate with the pharmacy benefit manager (PBM) using a discount to the AWP—eg, 14% off AWP, excluding dispensing fees. At the same time, the PBM may negotiate a lower rate with the pharmacy—eg, 15% off AWP. The PBM keeps the spread, or difference. The amounts we report are costs actually paid by the employer. To the extent there are any discrepancies between what the PBM and the employer pay, we agree with them that vigilance on the part of employers—and competition among PBMs—should limit them.

First Page Preview View Large
First page PDF preview
First page PDF preview
×